Our Biggest Takeaways From AAPS PharmSci 360

The AAPS PharmSci 360 meeting, held October 25–28 in New Orleans, gave formulation scientists, analytical chemists, regulatory affairs specialists, and CMC leaders a chance to take stock of a field in transition. AI appeared in sessions on formulation, validation, and drug discovery. USP’s proposed changes to excipient safety guidance drew attention, as did continuing debate over how much animal data drug developers really need. Across topics, a common message emerged: new tools can compress timelines, but regulators and quality leaders expect transparent, well-documented evidence in return.